GINA VISER: Open Payments
NPI 1316495492 · BOLIVAR, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,676 in 173 payments from 43 companies in 2025. Trend: 2023 $663 · 2024 $2,689 · 2025 $3,676
Food & beverage: $3,299Education: $377
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 16 | $308 |
| SEAGEN INC. | 3 | $277 |
| Janssen Biotech, Inc. | 14 | $260 |
| ABBVIE INC. | 10 | $235 |
| AstraZeneca Pharmaceuticals LP | 12 | $209 |
| Celgene Corporation | 12 | $195 |
| Merck Sharp & Dohme LLC | 7 | $149 |
| SOBI, INC | 4 | $143 |
| Gilead Sciences, Inc. | 7 | $139 |
| Daiichi Sankyo Inc. | 5 | $136 |
Products named: ENHERTU, REBLOZYL, KEYTRUDA, IMBRUVICA, SCEMBLIX, Trodelvy, RYBREVANT, MI CANCER SEEK.
Industry payments across MO — which companies pay providers there.
